SWK — Investor Presentation (November 2019)
29 slides from SWK's investor presentation, Nov 25, 2019
Slide 1: Collaborative Approach to Life Science Financing
Collaborative Approach to Life Science Financing
Slide 2: Forward-looking statements disclaimer
Statements in this presentation that are not strictly historical, and any statements regarding events or developments that we be lieve or anticipate will or may occur in the future are "forward - looking" statements within the meaning of the federal securities laws. There are a number of important f
Slide 3: SWK Holdings - Overview
• SWK targets $5mm to $20mm financings, a market niche that is largely ignored by larger market participants and generates attractive full - cycle returns • Business focus is secured financings and royalty monetizations, but will selectively consider equity - like opportunities and M&A Underserved,
Slide 4: Life Science Finance Opportunity
Life Science Finance Opportunity 4 Achieve high current yield from investment in non - correlated assets Access to capital is challenging for small/midsized life science cos - Few participants exist for sub - $20mm life science financings Life science products are highly portable - Approved & market
Slide 5: Value Creation Strategy
Value Creation Strategy 5 Deploy balance sheet capital into secured financing portfolio • SWK has established reputation as a go - to capital provider for this underserved market • Majority of financings structured with warrants or other upside features to enhance return profile Evaluate and pursue
Slide 6: Corporate Milestones
Corporate Milestones Pre - 2014 2014 2015 2016 2017 2018 2019 • Predecessor Kana Software assets sold to Kay Technologies; $450mm+ NOLs remained at sale • Winston Black and Brett Pope hired to launch life science technology finance strategy • $113mm raised through private placement and rights offeri
Slide 7: Portfolio Overview: 3Q19
Portfolio Overview: 3Q19 * GAAP value at September 30, 2019; does not include capital advances made subsequent to quarter end ** Finance Receivables plus Corporate Debt Securities *** Private warrants carried at zero cost/not valued on balance sheet • Income Producing Assets ** : $175.5mm • Finance
Slide 8: Financial Snapshot
Financial Snapshot * Defined as finance receivables, corporate debt securities, and investment in unconsolidated entity less non - controlling in terests ** During 2017 SWK incurred a $15.7mm provision for income taxes to reduce the carrying value of the deferred tax asset to acc ount for a reductio
Slide 9: Financing Strategy: Effective Yields
Financing Strategy 9 SWK Targets Low - to - Mid Teens Effective Yields 3Q19 Effective Yield of 13.8% * Includes non - accruals, marketable investments, and corporate debt securities; excludes marketable securities and warrants ** Includes non - accruals; effective yield is the rate at which income i
Slide 10: Current Structured Credit Portfolio
Current Structured Credit Portfolio 10 Eton Pharmaceuticals 11.14.19 $5 million – Structured Credit Misonix 9.27.19 $25.1 million – Structured Credit
Slide 11: Current Royalty Portfolio
Current Royalty Portfolio 11
Slide 12: Portfolio Realizations
Portfolio Realizations • As of November 13, 2019 SWK has exited 17 financings for a total 1.2x CoC return and 19% weighted average IRR ̶ 14 resulted in positive realizations with a cumulative 1.4x CoC and weighted average 31% IRR ̶ SynCardia position was sold to distressed private equity firm with S
Slide 13: Portfolio Realizations to Strategic Buyers
Portfolio Realizations to Strategic Buyers • Ten realizations to strategic buyers demonstrated a median 30% LTV of SWK’s original loan value • Seven of the ten businesses were not profitable at time of sale, validating SWK’s revenue and IP - based underwriting methodology 13 $ in mm Target Buyer Clo
Slide 14: Sourcing
Sourcing • SWK has a well - developed and diversified sourcing network ̶ SWK balances proprietary opportunities with deal flow from trusted, boutique investment banks and brokers • SWK typically faces limited competition due to proprietary sourcing network and focus on sub - $20mm financings • The d
Slide 15: Structured Debt and Royalties
• Primarily first lien senior secured loans, though will selectively evaluate second lien opportunities • Typically include covenants, prepayment penalties, origination and exit fees, and warrant coverage • Provide working capital to support product commercialization and M&A Structured Debt • Compan
Slide 16: Value Proposition to Partners
Value Proposition to Partners ̶ Smaller companies often don’t have financial profile to qualify for traditional financing sources ̶ Companies in this niche often have few options outside of a dilutive equity raise ̶ The IPO market is largely closed to companies of this size requiring expensive and d
Slide 17: Historical Financing: Narcan Royalty
Historical Financing: Narcan Royalty 17 ▪ Opiant is a publicly traded drug development company that receives a royalty on Narcan for developing the drug’s unique formulation o Novel formulation has a faster time to onset and more convenient and safer administration ▪ Opiant needed capital to pursue
Slide 18: Historical Financing: Galil Medical
Historical Financing: Galil Medical 18 ▪ In 2014, Galil was on the cusp of accelerating revenue growth, but was not yet cash - flow positive and could not tap traditional financing channels ▪ Galil needed additional capital to run clinical trials and expand its sales force OPPORTUNITY SOLUTION ▪ In
Slide 19: Enteris BioPharma Acquisition Rationale
• Natural extension to SWK’s existing royalty monetization business, which generates income via royalties on life science products in a mix of structures • Enteris offers opportunity to create wholly - owned portfolio of milestones and royalties on IP - protected biotherapeutics with substantial ups
Slide 20: Proven Technology, Late-Stage Commercial Partnerships, and Internal Pipeline
Proven Technology, Late - Stage Commercial Partnerships, and Internal Pipeline 6 Drug Delivery Technology • Peptelligence technology allows for oral delivery of drugs that are typically injected, including peptides and BCS class II, III, and IV small molecules • Extensive intellectual property estat
Slide 21: Enteris Transaction Terms
• $21.5mm paid upfront to acquire 100% of Enteris’ capital stock • Proceeds from Cara Therapeutics licensing agreement, which includes milestone payments and low - single digit royalties on sales o f Oral Korsuva™: ̶ Seller will receive 100% of $8.0mm upfront payment ̶ SWK will receive 60% of the fi
Slide 22: Leadership Team
Leadership Team Winston Black Chief Executive Officer ▪ Appointed CEO in 2016 ▪ Co - founded PBS Capital Management ▪ Prior leadership positions at Highland Capital Management, Mallette Capital Management and ATX Communications Charles Jacobsen Chief Financial Officer ▪ Appointed CFO in 2012 ▪ Curre
Slide 23: SWK - Rapidly-Growing Life Science Focused Specialty Finance Company
Custom financing solutions for commercial - stage healthcare companies and royalty owners Targeting $5mm to $20mm financings, a niche that is largely ignored by larger market participants Focus is secured financings and royalty monetizations, but will selectively consider equity - like opportunities
Slide 24: Balance Sheet
Balance Sheet 24 $ in 000s Sep-19 Dec-18 Dec-17 Dec-16 Dec-15 ASSETS Cash and cash equivalents 4,486$ 20,227$ 30,557$ 32,182$ 47,287$ Accounts receivable 2,452 2,195 1,637 1,054 1,127 Finance receivables 175,048 166,610 151,995 126,366 99,346 Marketable investments 1,946 - 1,856 2,621 5,286 Corporat
Slide 25: Income Statement
Income Statement 25 $ in 000s LTM Dec-18 Dec-17 Dec-16 Dec-15 Revenues Finance receivable interest income, including fees 27,758$ 25,978$ 26,877$ 15,747$ 17,265$ Pharmaceutical development services 149 - - - - Marketable investments interest income - - - 92 266 Income related to investments in uncon
Slide 26: Cash Flow Statement
Cash Flow Statement 26 $ in 000s,* LTM Dec-18 Dec-17 Dec-16 Dec-15 Cash flows from operating activities: Consolidated net income $19,642 $6,195 $8,251 $32,041 ($4,363) Adjustments to reconcile net income to net cash provided by operating activities: Income from investments in unconsolidated entity -
Slide 27: Reconciliation of Non-GAAP Adjusted Net Income
Reconciliation of Non - GAAP Adjusted Net Income 27 The table below eliminates provisions for income taxes, non - cash mark - to - market changes on warrant assets and SWK’s warrant liab ility, as well as, warrant - related debt issuance costs and stock compensation expense related to SWK’s equity r
Slide 28: Contact Information
Contact Information 28 • Winston Black: ̶ Phone: 972.687.7251 ̶ Email: [email protected] • Jody Staggs: ̶ Phone: 972.687.7252 ̶ Email: [email protected] • Office address: ̶ 14755 Preston Road, Ste 105 Dallas, TX 75254 • Website: www.swkhold.com
Slide 29: Collaborative Approach to Life Science Financing
Collaborative Approach to Life Science Financing